DOI QR코드

DOI QR Code

Changes in the Occurrence of Rotavirus Gastroenteritis before and after the Introduction of Rotavirus Vaccine among Hospitalized Pediatric Patients and Estimates of Rotavirus Vaccine Effectiveness

로타바이러스 백신 도입 후 소아 입원 환자에서의 로타바이러스 위장관염 발생 변화 및 로타바이러스 백신 효과 추정

  • Yoon, Jung Min (Department of Pediatrics, Hanyang University Seoul Hospital, Hanyang University College of Medicine) ;
  • Han, Tae Hwan (Department of Pediatrics, Hanyang University Seoul Hospital, Hanyang University College of Medicine) ;
  • Yoon, So Won (Department of Pediatrics, Hanyang University Seoul Hospital, Hanyang University College of Medicine) ;
  • Kim, Yong Joo (Department of Pediatrics, Hanyang University Seoul Hospital, Hanyang University College of Medicine) ;
  • Oh, Sung Hee (Department of Pediatrics, Hanyang University Seoul Hospital, Hanyang University College of Medicine)
  • 윤정민 (한양대학교병원 소아청소년과) ;
  • 한태환 (한양대학교병원 소아청소년과) ;
  • 윤소원 (한양대학교병원 소아청소년과) ;
  • 김용주 (한양대학교병원 소아청소년과) ;
  • 오성희 (한양대학교병원 소아청소년과)
  • Received : 2017.08.26
  • Accepted : 2017.10.28
  • Published : 2018.04.25

Abstract

Purpose: This study aimed to investigate the changes in the occurrence of rotavirus gastroenteritis (RGE) after the introduction of rotavirus vaccine and estimate rotavirus vaccine effectiveness in hospitalized children. Methods: We compared the retrospective data of 671 patients with acute gastroenteritis (AGE) admitted to the Department of Pediatrics, Hanyang University Seoul Hospital from January 1, 2014, to December 31, 2015, with retrospective data of 1,243 patients admitted to the same institution with AGE from January 1, 2004, to December 31, 2005. The vaccine effectiveness was estimated using a case-positive control test-negative study. Results: The proportion of RGE in AGE was significantly lower in 2014 to 2015 (9.0%, 48/531) than in 2004 to 2005 (22.7%, 282/1,243) (P<0.001). In particular, there was a significant decrease in the 6- to 11-, 12- to 23-, and 24- to 35-month-old groups (P<0.001), whose rotavirus vaccination rates were higher than the remaining age groups. The monthly distribution of patients with RGE in 2004 to 2005 was higher from November to May, peaked in January, followed by December and February. In 2014 to 2015, the monthly distribution of patients with RGE slightly peaked in January. In 2014 to 2015 study, the complete rotavirus vaccination rate was 66.0% (332/503) and incomplete vaccination rate was 6.2% (31/503). Presumed rotavirus vaccine effectiveness was 83.3% (95% confidence interval [CI], 60.5% to 92.9%) in the complete vaccination group and 27.4% (95% CI, -163.7% to 80.0%) in the incomplete group. Conclusions: The proportion of RGE in AGE has markedly decreased since the introduction of rotavirus vaccines, and improving vaccination coverage will further reduce the burden of RGE in Korea.

목적: 로타바이러스(rotavirus [RV]) 백신 도입에 따른 소아 입원 환자에서의 로타바이러스 장염(rotavirus gastroenteritis [RGE]) 발생 변화와 백신 효과를 추정하였다. 방법: 2014-2015년과 2004-2005년, 두 기간 동안 한양대학교 서울병원 소아청소년과에 급성 장염(acute gastroenteritis [AGE])으로 입원한 환자의 자료를 후향적으로 비교 분석하였다. 백신 효과는 환자 검사-음성 대조군 연구를 통해 추정하였다. 결과: AGE에서의 RGE 비율은 2004-2005년(22.7%)에 비해 2014-2015년(9.0%)에 유의하게 감소하였다(P<0.001). 2014-2015년 RV 백신 완전접종률은 66.0%, 불완전접종률은 6.2%로, 백신의 예방 효과는 완전접종자에서 83.3% (95% confidence interval [CI], 60.5%-92.9%), 불완전접종자에서는 27.4% (95% CI, -163.7%-80.0%)였다. 결론: RV 백신이 도입된 이후 RGE 발생이 뚜렷이 감소하였다. 백신접종률을 향상시킴으로써 RGE로 인한 질병 부담을 더욱 낮출 수 있을 것으로 기대된다.

Keywords

References

  1. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009;84:533-40.
  2. World Health Organization. Estimated rotavirus deaths for children under 5 years of age: 2013, 215,000 [Internet]. Geneva: WHO; c2018 [cited 2018 Mar 14]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/rotavirus/en/.
  3. World Health Organization. Immunization coverage [Internet]. Geneva: WHO; c2018 [cited 2018 Mar 14]. Available from: http://www.who.int/mediacentre/factsheets/fs378/en/.
  4. Safadi MA, Berezin EN, Munford V, Almeida FJ, de Moraes JC, Pinheiro CF, et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. Pediatr Infect Dis J 2010;29:1019-22.
  5. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. https://doi.org/10.1056/NEJMoa052664
  6. Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010; 28:754-8. https://doi.org/10.1016/j.vaccine.2009.10.075
  7. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011;53:245-53. https://doi.org/10.1093/cid/cir307
  8. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011;30(1 Suppl):S21-4. https://doi.org/10.1097/INF.0b013e3181fefc51
  9. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009;301:2243-51. https://doi.org/10.1001/jama.2009.756
  10. Lanzieri TM, Costa I, Shafi FA, Cunha MH, Ortega-Barria E, Linhares AC, et al. Trends in hospitalizations from all-cause gastroenteritis in children younger than 5 years of age in Brazil before and after human rotavirus vaccine introduction, 1998-2007. Pediatr Infect Dis J 2010;29:673-5. https://doi.org/10.1097/INF.0b013e3181da8f23
  11. Yen C, Armero Guardado JA, Alberto P, Rodriguez Araujo DS, Mena C, Cuellar E, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 2011;30(1 Suppl):S6-10. https://doi.org/10.1097/INF.0b013e3181fefa05
  12. The Korean Pediatric Society. Rotavirus vaccine, immunization guideline. 8th ed. Seoul: The Korean Pediatric Society, 2015:226-38.
  13. Choi UY, Lee SY, Ma SH, Jang YT, Kim JY, Kim HM, et al. Epidemiological changes in rotavirus gastroenteritis in children under 5 years of age after the introduction of rotavirus vaccines in Korea. Eur J Pediatr 2013;172:947-52. https://doi.org/10.1007/s00431-013-1974-y
  14. Seo JK, Sim JG. Overview of rotavirus infections in Korea. Pediatr Int 2000;42:406-10. https://doi.org/10.1046/j.1442-200x.2000.01250.x
  15. Lee HS, Kim DY, Kim JA, Choi SH. The epidemiological trend of rotavirus gastroenteritis in children in a single center from 2004 to 2012: a retrospective study. Korean J Pediatr Infect Dis 2014;21:181-90.
  16. Yoon SW. Study on nosocomial gastroenteritis in hospitalized children [master's thesis]. Seoul: Department of Medical Science, Hanyang University Graduate School; 2009.
  17. Tate JE, Patel MM, Cortese MM, Payne DC, Lopman BA, Yen C, et al. Use of patients with diarrhea who test negative for rotavirus as controls to estimate rotavirus vaccine effectiveness through case-control studies. Clin Infect Dis 2016;62 Suppl 2:S106-14. https://doi.org/10.1093/cid/civ1014
  18. Immergluck LC, Parker TC, Jain S, Laghaie E, Spandorfer P, Jerris RC, et al. Sustained effectiveness of monovalent and pentavalent rotavirus vaccines in children. J Pediatr 2016;172:116-20. https://doi.org/10.1016/j.jpeds.2016.01.042
  19. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010;125:e199-207. https://doi.org/10.1542/peds.2009-1021
  20. Leshem E, Givon-Lavi N, Tate JE, Greenberg D, Parashar UD, Dagan R. Real-world effectiveness of pentavalent rotavirus vaccine among Bedouin and Jewish children in Southern Israel. Clin Infect Dis 2016;62 Suppl 2:S155-60. https://doi.org/10.1093/cid/civ1012
  21. Fujii Y, Noguchi A, Miura S, Ishii H, Nakagomi T, Nakagomi O, et al. Effectiveness of rotavirus vaccines against hospitalisations in Japan. BMC Pediatr 2017;17:156. https://doi.org/10.1186/s12887-017-0916-7
  22. Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine 2017;35:4796-800. https://doi.org/10.1016/j.vaccine.2017.07.003
  23. El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG. Projecting the effectiveness of RotaTeq(R) against rotavirus-related hospitalizations and deaths in six Asian countries. Hum Vaccin 2011;7:506-10. https://doi.org/10.4161/hv.7.5.14620
  24. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Gentsch JR, Stockman LJ, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008;122:1235-43. https://doi.org/10.1542/peds.2007-3378
  25. Bass DM. Rotaviruses, caliciviruses, and astroviruses. In: Kliegman RM, Nelson WE, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier, 2016:1616-8.
  26. Sohn TY, Lee CJ, Kim YJ, Kang MJ, Kim SH, Lee SY, et al. Clinical and epidemiological study of 1,165 hospitalized cases of rotaviral gastroenteritis before and after the introduction of rotavirus vaccine, 2006-2013. Korean J Pediatr Infect Dis 2014;21:174-80.
  27. Suzuki H, Sakai T, Tanabe N, Okabe N. Peak rotavirus activity shifted from winter to early spring in Japan. Pediatr Infect Dis J 2005;24:257-60. https://doi.org/10.1097/01.inf.0000154327.00232.4d
  28. Torok TJ, Kilgore PE, Clarke MJ, Holman RC, Bresee JS, Glass RI. Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. National Respiratory and Enteric Virus Surveillance System Collaborating Laboratories. Pediatr Infect Dis J 1997;16:941-6. https://doi.org/10.1097/00006454-199710000-00007
  29. Kang JO, Kim MN, Kim J, Suh HS, Yoon Y, Jang S, et al. Epidemiologic trends of rotavirus infection in the Republic of Korea, July 1999 through June 2002. Korean J Lab Med 2003;23:382-7.
  30. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. https://doi.org/10.1056/NEJMoa052434
  31. Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R) (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin 2011;7:563-8. https://doi.org/10.4161/hv.7.5.15406
  32. Gurgel RQ, Cuevas LE, Vieira SC, Barros VC, Fontes PB, Salustino EF, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis 2007;13: 1571-3. https://doi.org/10.3201/eid1310.070412
  33. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008; 7:345-53. https://doi.org/10.1586/14760584.7.3.345
  34. Shim JO, Chang JY, Shin S, Moon JS, Ko JS. Changing distribution of age, clinical severity, and genotypes of rotavirus gastroenteritis in hospitalized children after the introduction of vaccination: a single center study in Seoul between 2011 and 2014. BMC Infect Dis 2016;16:287. https://doi.org/10.1186/s12879-016-1623-y
  35. Choe YJ, Yang JJ, Park SK, Choi EH, Lee HJ. Comparative estimation of coverage between national immunization program vaccines and non-NIP vaccines in Korea. J Korean Med Sci 2013;28:1283-8. https://doi.org/10.3346/jkms.2013.28.9.1283
  36. Korean Centers for Disease Control and Prevention. National immunization survey in South Korea, 2013. Public Health Wkly Rep 2014;7;449-54.

Cited by

  1. 2015년부터 2018년까지 일개 이차병원에서 동정된 소아 급성 위장염 원인 병원체의 분자진단과 역학의 임상적 연구 vol.27, pp.2, 2018, https://doi.org/10.14776/piv.2020.27.e13
  2. Molecular epidemiologic trends of norovirus and rotavirus infection and relation with climate factors: Cheonan, Korea, 2010-2019 vol.18, pp.12, 2020, https://doi.org/10.14400/jdc.2020.18.12.425
  3. Causes of acute gastroenteritis in Korean children between 2004 and 2019 vol.64, pp.6, 2021, https://doi.org/10.3345/cep.2020.01256
  4. Effects of climatic factors and particulate matter on Rotavirus A infections in Cheonan, Korea, in 2010-2019 vol.28, pp.32, 2018, https://doi.org/10.1007/s11356-021-13852-3